Haematological oncology Group, Academic Haematology, Medical School, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Stem Cells Int. 2010;2010:431909. doi: 10.4061/2010/431909. Epub 2009 Aug 26.
The report describes the feasibility of the addition of multiple viable HLA-mismatched unrelated cord blood units, to a low cell number matched unrelated cord, to assist clinical engraftment. An ablative stem cell transplant was performed in an adult with relapsed acute lymphoblastic leukaemia (ALL), using a single HLA-matched cord blood unit (mononuclear cell dose 0.8 × 10(7)), supported by six mismatched cord blood units (one unit per 10 kg recipient weight). No adverse reaction occurred following the infusion of mismatched units and engraftment of the suboptimal-dose matched unit occurred rapidly, with no molecular evidence of engraftment of mismatched cords. Early molecular remission of ALL was demonstrated using a novel PCR for a mitochondrial DNA mutation in the leukaemic clone. The cell dose of the matched cord was well below that recommended to engraft a 70 kg recipient. We suggest that a factor or factors in the mismatched cords enhanced/supported engraftment of the matched cord.
该报告描述了在低细胞数匹配的无关脐带血基础上添加多个可行的 HLA 不合无关脐带血单位以辅助临床植入的可行性。在一名复发急性淋巴细胞白血病(ALL)的成年患者中进行了清髓性干细胞移植,使用了单个 HLA 匹配的脐带血单位(单核细胞剂量 0.8×10(7)),并由六个不合脐带血单位支持(每个 10kg 受者体重一个单位)。输注不合单位后未发生不良反应,亚最佳剂量匹配单位快速植入,未发现不合脐带的植入分子证据。使用白血病克隆中线粒体 DNA 突变的新型 PCR 检测到 ALL 的早期分子缓解。匹配脐带的细胞剂量远低于推荐用于植入 70kg 受者的剂量。我们认为,不合脐带中的某种因素增强/支持了匹配脐带的植入。